Lexicon Gains FDA Clearance for Phase 3 Pilavapadin Trial in Diabetic Neuropathy; LXRX Shares Rise

Lexicon Pharmaceuticals has received U.S. Food and Drug Administration (FDA) authorization to begin a Phase 3 clinical trial of pilavapadin for treating diabetic peripheral neuropathic pain, the company announced January 21, 2026. The pivotal trial will enroll approximately 500 patients across multiple U.S. sites, evaluating efficacy and safety over a 12-week period. Pilavapadin, an oral Factor XIa inhibitor, aims to address chronic nerve pain without central nervous system side effects common in current therapies. LXRX shares climbed 7.3% in after-hours trading following the announcement. If successful, Lexicon plans to submit a New Drug Application (NDA) by mid-2028. Diabetic neuropathy affects over 18 million adults in the U.S., representing a potential multibillion-dollar market opportunity.